Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 12, 2025The European Journal of Health EconomicsOpen Access

Cost-effectiveness of testing biofluid biomarkers to diagnose Alzheimer’s disease: a systematic review

View Full Paper
Ask AI
Bookmark
Share

Authors

HJHongzhou JiangSESergio EscamillaMBMolly Beestrum

Discussion

Loading...

Member takes

Overview

Systematic review shows cost-effectiveness of biofluid biomarker tests in Alzheimer’s disease, highlighting the importance of timely diagnosis.

Key Points

  • Evaluate the cost-effectiveness of biofluid biomarkers in diagnosing Alzheimer’s disease.
  • Systematic review of studies up to October 2024
  • Economic evaluations of blood and cerebrospinal fluid biomarker testing
  • Used CHEERS 2022 criteria for quality assessment
  • Nine studies included: six on CSF tests, three on blood tests
  • CSF tests were mostly cost-effective compared to neurocognitive assessments or neuroimaging
  • Blood tests showed mixed cost-effectiveness results
  • Key factors included AD prevalence and diagnostic accuracy
  • Studies met ~80% of CHEERS criteria

Cite This Study

Jiang et al. (2025) studied this question.

synapsesocial.com/papers/6941aae10f5af7fd17df5a25https://doi.org/10.1007/s10198-025-01877-1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Blood-based biomarkers for early diagnosis of Alzheimer’s disease: a current systematic review of diagnostic accuracy studies2026
  2. 2Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment2024 · 12 citations
  3. 3The Effect of Early Diagnosis of Alzheimer’s Disease: A Short Systematic Review2025
  4. 4Cost-effectiveness analysis of blood-based biomarker testing in the diagnosis of Alzheimer’s disease pathology2026 · 3 citations
  5. 5Progress in Defining Blood Biomarkers for Alzheimer's Disease Based on Biochemical Mass Spectrometry Platforms2026